Screener
Vir Biotechnology, Inc. VIR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031471
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | (4,226) | (1,415) |
| Accrued liabilities and other long-term liabilities | (17,223) | 18,012 |
| Operating lease liabilities | (2,273) | (1,796) |
| Net cash used in operating activities | (132,386) | (78,116) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sale of equipment | — | 281 |
| Purchases of long-lived assets | (390) | (1,629) |
| Purchases of investments | (158,374) | (173,694) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s operating cash flow?
- Vir Biotechnology, Inc. (VIR) reported operating cash flow of -$132.39M in Q1 2026.
- How has Vir Biotechnology, Inc.'s operating cash flow changed year-over-year?
- Vir Biotechnology, Inc.'s operating cash flow decreased by 69.5% year-over-year, from -$78.12M to -$132.39M.
- What is the long-term trend for Vir Biotechnology, Inc.'s operating cash flow?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s operating cash flow has grown at a -38.2% compound annual growth rate (CAGR), from $1.66B to -$391.78M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Vir Biotechnology, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude